Advertisement
Advertisement

MREO

MREO logo

Mereo Biopharma Group Plc - ADR

3.52
USD
+0.12
+3.53%
Dec 18, 13:44 UTC -5
Open

Mereo Biopharma Group Plc - ADR Profile

About

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo BioPharma Group plc is based in LONDON.

Info & Links

CEO

Denise Scots-Knight

Headquarters

ONE CAVENDISH PLACE, FOURTH FLOOR
LONDON, X0 W1G0QF, UNITED KINGDOM

Auditor

PricewaterhouseCoopers LLP

Share holders

--

Employees

33

Mereo Biopharma Group Plc - ADR Statistics

Valuation Measures

Market Capitalization2

546.13M

Enterprise Value

502.10M

Enterprise Value/EBITDA(ttm)

-51.49

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

7.98

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

31.85%

Operating Margin(ttm)

--

Profit Margin(ttm)

-227.70%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

-73.74%

Return on Assets(ttm)

--

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-9.75M

Net Income Available to Common(ttm)

-8.95M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

--

52-Week Change

69.23%

S&P 500 52-Week Change

27.80%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

140.27M

Dividend Yield

0.00%

Float4

0.00

% Held by Insiders

--

% Held by Institutions

62.83%

Balance Sheet

Total Cash(mrq)

48.66M

Total Cash Per Share(mrq)

0.35

Total Debt(mrq)

4.63M

Total Debt/Equity(mrq)

7.65%

Current Ratio(mrq)

6.10%

Quick Ratio(mrq)

6.10%

Book Value Per Share(mrq)

0.47

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.15

Free Cash Flow(ytd)

-23.41M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement